ArticleAsian Pacific journal of cancer prevention : APJCP2025
Spexin Adipokinin and TRPM2 ION Channel in Lung Cancer Use as a Bıomarker in Hıstopathologic Diagnosis.
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pathophysiological significance of the TRPM2 ion channel as a potential target in cancer, neurological disorders, and ischemia/reperfusion injury.Pharmacological research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung cancer is the most common cancer with the highest mortality rate. Spexin peptide acts as a potential regulatory factor in glucose and energy metabolism in this cancer type. It has been reported that TRPM2 ion channel is formed by oxidative stress and stimulates Ca2++ influx in cancer patients.
objectiveIn our study, we aimed to immunohistochemically determine the activity levels of Spexin peptide and TRPM2 ion channels in lung cancer patients and to differentiate their levels according to cancer type.
methodsTo determine the effects of these peptides and ion channels in lung cancer, 30 cases with lung cancer and 30 randomised control groups were formed. The activity levels of Spexin peptide and TRPM2 ion channels in different types of lung cancer and non-cancerous groups were compared.
resultsThe study examined lung cancer subtypes (Adeno Ca, SCC, and Small Cell Ca) and a control group. Spexin and TRPM2 levels were significantly higher in Adeno Ca and SCC compared to controls and Small Cell Ca. Small Cell Ca showed no significant difference from controls. No differences were found between Adeno Ca and SCC.
conclusionImmunoreactivity levels of these markers were found to be higher in adenocarcinoma and squamous cell lung cancer tissues than in small cell cancer and non-cancerous tissues. In conclusion, spexin and TRPM2 ion channel levels can be evaluated as a marker in adenocarcinoma and squamous cell lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.